Acelyrin IPO

acelyrin.com

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Founded2020
Total Funding to Date$558MM
Register for Details

For more details on financing and valuation for Acelyrin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Acelyrin Ticker Symbol

Acelyrin does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Acelyrin Stock Price

The stock price for Acelyrin will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Acelyrin

Cowen Group
Marshall Wace
Matrix Partners
Decheng Capital
Westlake Village BioPartners
OrbiMed Healthcare Fund Management
Samsara Biocapital
venBio
RTW Investments
Surveyor
Tybourne Capital Management

Acelyrin Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/9/2022 Series C $300MM raised $XXX.XX $XXX.XX
11/16/2021 Series B $250MM raised $XXX.XX $XXX.XX
12/15/2020 Series A $8MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Acelyrin in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector